Filtered By:
Source: Cancer Science
Drug: Gleevec
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Leukemogenic kinase FIP1L1 ‐PDGFRA and a small ubiquitin‐like modifier E3 ligase, PIAS1, form a positive cross‐talk through their enzymatic activities
In conclusion, our results suggest that sumoylation by PIAS1 is a potential target in the treatment of FIP1L1‐PDGFRA‐positive chronic eosinophilic leukemia.
A leukemogenic fusion kinase FIP1L1‐PDGFRA co‐localizes with a SUMO E3 ligase PIAS1 in nucleus. PDGFRA‐C lacking the FIP1L1 portion mainly locates in cytoplasm.
Source: Cancer Science - February 27, 2017 Category: Cancer & Oncology Authors: Makoto Ibata, Junko Iwasaki, Yoichiro Fujioka, Koji Nakagawa, Stephanie Darmanin, Masahiro Onozawa, Daigo Hashimoto, Yusuke Ohba, Shigetsugu Hatakeyama, Takanori Teshima, Takeshi Kondo Tags: Original Article Source Type: research
A leukemogenic kinase, FIP1L1 ‐PDGFRA, and a SUMO E3 ligase, PIAS1, form a positive crosstalk via their enzymatic activities
In conclusion, our results suggest that sumoylation by PIAS1 is a potential target in the treatment of FIP1L1‐PDGFRA‐positive chronic eosinophilic leukemia.
This article is protected by copyright. All rights reserved.
Source: Cancer Science - December 12, 2016 Category: Cancer & Oncology Authors: Makoto Ibata, Junko Iwasaki, Yoichiro Fujioka, Koji Nakagawa, Stephanie Darmanin, Masahiro Onozawa, Daigo Hashimoto, Yusuke Ohba, Shigetsugu Hatakeyama, Takanori Teshima, Takeshi Kondo Tags: Original Article Source Type: research
